Page last updated: 2024-12-08

2'fluoro-2'-deoxyuridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID150851
CHEMBL ID2385615
SCHEMBL ID221951
MeSH IDM0112973

Synonyms (37)

Synonym
2'-fluoro-2'-deoxyuridine
784-71-4
2'-deoxy-2'-fluorouridine ,
uridine, 2'-deoxy-2'-fluoro-
1-(3-fluoro-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1h-pyrimidine-2,4-dione
1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
STK368458
1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
1-((2s,3s,4s,5s)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione;2'-deoxy-2'-fluorouridine; 2-fdu
A839431
2'fluoro-2'-deoxyuridine
unii-y2yc903qw8
y2yc903qw8 ,
CHEMBL2385615
AKOS015896926
1-(2-deoxy-2-fluoro-.beta,-d-ribofuranosyl)uracil
1-((2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl)pyrimidine-2,4-dione
HG1163
SCHEMBL221951
1-(2-deoxy-2-fluoro-beta-d-ribofuranosyl)uracil
2'-deoxy-2'-fluoro-uridine
2'-deoxy-2'- fluorouridine
UIYWFOZZIZEEKJ-XVFCMESISA-N
J-700032
2'-deoxy-2'-(r)-fluoro-uridine
2'-deoxy-2'-fluoro-l-uridine
1-((2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
mfcd01317293
CS-W014119
DS-10495
622785-69-7
Q27294189
1-(2-deoxy-2-fluoropentofuranosyl)-4-hydroxypyrimidin-2(1h)-one
DTXSID50999738
HY-W013403
PD158307
BP-58615
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID102832Inhibition of growth of normal human lymphocytic cells1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Nucleosides. 123. Synthesis of antiviral nucleosides: 5-substituted 1-(2-deoxy-2-halogeno-beta-D-arabinofuranosyl)cytosines and -uracils. Some structure-activity relationships.
AID139991Inhibition constant for influx competition with [6-3H]thymidine in mouse erythrocytes1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and tumor uptake of 5-82Br- and 5-131I-labeled 5-halo-1-(2-fluoro-2-deoxy-beta-D-ribofuranosyl)uracils.
AID1204707Antiviral activity against RSV A2 infected in human Hep2 cells assessed as protection against virus-induced cytopathic effect after 4 days by Cell-Titer Glo assay2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID1204710Inhibition of human mitochondrial DNA polymerase gamma large subunit/DNA polymerase gamma accessory subunit using 32P-D19/D36 as DNA primer/template assessed as single nucleotide incorporation rate at 100 uM after 5 to 90 mins by PAGE analysis relative to2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID1204709Inhibition of human mitochondrial RNA polymerase using 5'-32P-R12/D18 as RNA/DNA template assessed as single nucleotide incorporation rate at 500 uM after 0.17 to 30 mins by PAGE analysis2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID1204708Inhibition of RSV A2 RNA-dependent RNA polymerase expressed in human Hep2 cells using ATP, GTP, UTP, CTP and 1.5 uCi [alpha-32P] NTP as substrate assessed as reduction of total radiolabled transcript after 90 mins by agarose gel electrophoresis2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID750143Inhibition of HCV 1b NS5b polymerase2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Evaluation of 2'-α-fluorine modified nucleoside phosphonates as potential inhibitors of HCV polymerase.
AID86026Antiherpetic activity against HSV-11983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Nucleosides. 123. Synthesis of antiviral nucleosides: 5-substituted 1-(2-deoxy-2-halogeno-beta-D-arabinofuranosyl)cytosines and -uracils. Some structure-activity relationships.
AID84937Antiherpetic activity against HSV-21983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Nucleosides. 123. Synthesis of antiviral nucleosides: 5-substituted 1-(2-deoxy-2-halogeno-beta-D-arabinofuranosyl)cytosines and -uracils. Some structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (30.77)18.7374
1990's3 (23.08)18.2507
2000's2 (15.38)29.6817
2010's3 (23.08)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.49 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index37.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]